AstraZeneca
NEWS
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
It was another busy week for clinical trial announcement. Here’s a look.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
JOBS
IN THE PRESS